(Q39608639)

13 September 2017

1 reference

title

Aminoglycosides: current role in antimicrobial therapy (English)

1 reference

13 September 2017

Cunha BA

1

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 January 1988

1 reference

13 September 2017

1 reference

13 September 2017

volume

8

1 reference

13 September 2017

issue

6

1 reference

13 September 2017

page(s)

334-350

1 reference

Staphylococcus aureus. The persistent pathogen (first of two parts).

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

In vitro evaluations of amikacin: an assessment of the currently used methods of disk diffusion and dilution susceptibility, antimicrobial synergy, and the measurement of amikacin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Aminoglycoside antibiotics in infectious diseases. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Acetylation of amikacin, a new semisynthetic antibiotic, by Pseudomonas aeruginosa carrying an R factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Transfer of amikacin resistance by closely related plasmids in members of the family Enterobacteriaceae isolated in Chile

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Review of epidemic aminoglycoside resistance worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Aminoglycoside resistance: a worldwide perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Use of aminoglycosides in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Five-year surveillance of aminoglycoside usage in a university hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Surveillance of aminoglycoside resistance. European data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Treatment of Pseudomonas and Serratia infections with ceftazidime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Imipenem/cilastatin therapy of bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Imipenem/cilastatin: general experience in a community hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Pneumonia treated with imipenem/cilastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Combination therapy and monotherapy in the treatment of severe infection in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

A Comparative Study of the Activity of Cefamandole and Other Cephalosporins and Analysis of the -Lactamase Stability and Synergy of Cefamandole with Aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Global and Effective Synergism of Amikacin, Gentamicin or Tobramycin when Combined with Carbenicillin against Pseudomonas Aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Management of sepsis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Management of intra-abdominal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Aminoglycosides in gynecologic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Therapeutic initiatives for the avoidance of aminoglycoside toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Controlled Comparison of Amikacin and Gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparison of Amikacin and Tobramycin in the Treatment of Infection in Patients with Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Prospective comparative study of efficacy and toxicity of netilmicin and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Controlled Comparison of Gentamicin and Tobramycin Nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Aztreonam compared with gentamicin for treatment of serious urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1988.TB04092.X

10.1002/J.1875-9114.1988.TB04092.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference